Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Career conservative and former congressman Dave Weldon will, if confirmed, act as director of the Centers of Disease Control ...

While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand ...

RFK Jr. as HHS head is perhaps President-elect Donald Trump’s most controversial Cabinet pick now that Matt Gaetz has ...

Makary is a pancreatic surgeon at Johns Hopkins who became known for battling medical mistakes and in recent years has been ...